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ABSTRACT 
      The genus Ebola virus first was recognized in 1976, when two outbreaks occurred in Zaire and Sudan. 
Ebola virus disease (EVD) is a highly contagious disease that can affect both human and nonhuman 
primates: Zaire ebolavirus (ZEBOV), Sudan ebolavirus (SEBOV), Côte d’Ivoire ebolavirus (CEBOV), 
Bundibugyo ebolavirus (BEBOV) and Reston ebolavirus (REBOV) are five members of the Filoviridae 
family that can cause haemorrhagic fever. EVD is transmitted by direct contact with contaminated blood or 
other biological fluids of the infected animals such as chimpanzees, gorillas, fruit bats, monkeys, forest antelope 
and porcupines found ill or dead or in the rainforest. Ebola is responsible for different clinical futures that can be 
ranged from fever, headache, arthralgia, myalgia, abdominal pain, anorexia and vomiting to severe respiratory 
disorders, viral hemorrhagic fever, cardio-vascular disorders and hypovolaemic shock.  Although there is no 
specific treatment for EVD, considerable advances like use of monoclonal antibody, intefron and Favipiravir/T-
705 as effective chemotherapeutic agent in treatment of EBV have been made. To date, 25 outbreaks of EVD 
have been reported. Hence, EVD as a zoonotic disease should be more focused not only in endemic area but also 
in throughout the world. Awareness of the disease and routes of transmission and also continuous surveillance to 
combat disease and outbreaks is necessary. 
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INTRODUCTION  
      Ebola virus as a causative agent of a severe form 
of viral haemorrhagic fever has drawn international 
attention particularly for the largest outbreaks in 
West African countries. Ebola haemorrhagic fever 
(EHF) is a zoonosis disease that can affect both 
human and nonhuman primates and caused by 
members of the Filoviridae family: Zaire ebolavirus 
(ZEBOV), Sudan ebolavirus (SEBOV), Côte 
d’Ivoire ebolavirus (CEBOV), Bundibugyo 
ebolavirus (BEBOV) and Reston ebolavirus 
(REBOV) [1]. Ebola virus was first documented in 
1976 in Republic of the Congo near the Ebola River 
[2]; since then, outbreaks have been reported. So far 
about 25 outbreaks of Ebola have been 
approximately recognized that all occurring in 
Africa, with fatality rates of 25% to 90% [3, 4]. 
Ebola virus disease (EVD) which was known as 
EHF is a highly contagious anthropozoonotic 
disease that can cause by direct contact with 
contaminated blood or other biological fluids of the 
infected animals such as chimpanzees, gorillas, fruit 
bats, monkeys, forest antelope and porcupines found 
ill or dead or in the rainforest [2, 5, 6]. The Ebola 
virus with a relatively high mortality rate 20-90% 
(depending on the virus species) and the possibility 
of misuse as a biological weapon is a serious threat 
to the worldwide. The natural reservoir host of 
Ebola virus remains unknown. However, on the 
basis of evidence and the nature of similar viruses, 
many researchers believe that this virus is animal-
borne and bats are the most likely reservoir [7].  
Despite ongoing efforts to recognize the molecular 
biology and pathogenesis of Ebola virus during the 
past two decades, there are ambiguities 
regarding virulence factors, host responses, 
treatment methods and vaccines of EV. The purpose 
of this review is to present essential and up-to-date 
information required to identify, management, 
prevention and treatment of EVD. 
 




Virology and Pathogenic mechanisms 
     Ebola virus and Marburg virus are members of 
the family Filoviridae and is included in the order 
Mononegavirales[8]. They are similar to families 
of arenaviruses, bunyaviruses, and flaviviruses 
which are cause viral hemorrhagic fever. Ebola 
virus has a lipid envelope derived from the host 
cell, negative single strand RNA with a 19 kb 
genome. EV particles have a uniform diameter of 
80 nm but can greatly vary in length, with a mean 
unit length of 12000 nm [9]. The seven genes are 
ordered in the genome as follows: 3'-UTR- NP 
(nucleoprotein)– VP35 (virion protein) -VP40- 
GP (glycoprotein)-VP30-VP24- L (RNA-
dependent RNA polymerase)-5'-UTR. All of these 
genes with the exception of the glycoprotein gene 
are monocistronic [9, 10]. The glycoprotein or 
peplomer glycoprotein as a transmembrane 
surface protein makes up the viral surface spikes 
in the form of trimers 10 nm in length. The Ebola 
virus glycoproteins (structural 
glycoprotein GP1,2) are responsible for binding 
the virus to target-cells and also aid the virus on 
immune evasion [10, 11]. The viral RNA 
polymerase, encoded by the L gene, partially 
uncoats the nucleocapsid and transcribes the 
genes into positive-strand mRNAs, which are then 
translated into structural and nonstructural 
proteins. The ribonucleoprotein complex of virus 
composed of  the RNA genome, nucleoprotein 
and four structural proteins VP24 (interferes with 
interferon signaling), VP30 (virion structural 
protein 30), VP35 (interferon antagonist) and 
VP40 (matrix protein and mediates particle 
formation [10, 12]. The exact mechanism of 
Ebola virus entry to host cells remains poorly 
understood but several studies demonstrated 
clathrin-mediated endocytosis, caveolin-mediated 
endocytosis and macropinocytosise pathways of 
entry. Macropinocytosis is the most likely entry 
mechanism employed by the EV. The early 
targets of the virus are monocytes and 
macrophages, dendritic cells, liver cells, 
fibroblasts, hepatocytes, adrenal cortical cells and 
endothelial cells. The life cycle of Ebola virus is 
begun with attaching a virus by GP to specific 
cell-surface receptors such as C-type lectins, DC-
SIGN, or integrins, via fusion of the viral 
envelope with cellular membranes [13, 14]. 
Interaction of GP with cell surface receptors can 
trigger macropinocytosis. Soluble glycoprotein 
(sGP) is expressed through RNA editing by 
infected cells and is an important distinction of 
Ebola virus from other Mononegavirales [15]. 
Previous studies were reported sGP, but not GP, 
can bind to neutrophils and inhibit early 
neutrophil activation while both type of GP can 
neutralize antibodies. After macropinocytosis, 
virion traps to early endosomes and fuse with 
lysosomes then the viral envelope is cleaved. This 
processing appears to allow the virus to release 
the viral nucleocapsid within host cytoplasm [13, 
15]. Viral transcription is initiated at the leader 
end of the genome with the binding of the 
polymerase complex. RNA genome is transcribed 
into seven monocistronic mRNAs. According to 
the template, NP mRNA is the most 
abundant species and the L mRNA is the least 
abundant. VP30 was shown to be important for 
transcription reinitiation of subsequent genes and 
is essential for the viral life cycle while VP24 is 
an inhibitor for transcription and replication of the 
Ebola virus genome. The VP24 protein is unique 
of EV and can influence on genome replication, 
transcription and nucleocapsid assembly. 
Replication presumably starts when enough 
nucleoprotein is present to encapsidate neo-
synthetized antigenomes and genomes [16, 17]. 
Newly synthesized structural proteins and 
genomes self-assemble and accumulate near the 
inside of the cell membrane. Virions bud via host 
ESCRT (endosomal sorting complex required for 
transport) gaining their envelopes from the 
cellular membrane which they bud. The mature 
progeny particles then infect other cells to repeat 
the cycle. The genetics of the Ebola virus are 
difficult to study because of EBOV's virulent 
characteristics [18-21]. As previously mentioned, 
Ebola viruses have five subtypes including: Zaire 
(EOBV), Sudan (SUDV), Bundibugyo (BDBV), 
Tai Forest (TAFV) and Reston (RESTV). Each 
subtype has specific biological characteristic and 
virulence [2]. 
Epidemiology  
    Ebola virus first was reported in 1976 in two 
outbreaks that were occurred in Zaire and Sudan. 
In 1995, an epidemic caused by the Zaire species 
caused several hundred cases in Kiewit, 
Democratic Republic of the Congo, and in 2000, 
the Sudan virus infected more than 400 people in 
 




Gulu, Uganda [3, 4]. To date, more than 25 
outbreaks of EVD have been reported [22]. 
Outbreaks of Ebola virus disease have been 
confined to Sub-Saharan Africa [23]. The Ebola 
outbreak in West Africa was first reported by 
World Health Organization (WHO) in March 
2014 is the largest outbreak yet [24]. It started in 
Guinea in late 2013 then spreading across land 
borders to Sierra Leone and Liberia, by air to 
Nigeria (one traveller) and USA (one traveller), 
and by land to Senegal (one traveller) and Mali 
(two travellers) [25]. As of October 25, 2014, out 
of 10,141 suspected cases (5692 laboratory-
confirmed cases) and 4922 deaths was reported by 
WHO and the Centers for Disease Control and 
Prevention [26]. Twenty seven cases (20 cases 
from Nigeria, 4 from the United States, and one 
each from Senegal, Mali, and Spain) were 
reported as travel-associated cases and localized 
transmissions [27]. 
On 24 August, 2014, outbreak occurred in 
multiple villages in the Democratic Republic of 
the Congo in Equatorial Africa. The index case 
was a pregnant woman from Ikanamongo Village 
who butchered a bush animal. This outbreak had a 
zoonotic origin different from the current 
epidemic in West Africa. A total of 66 cases, 
including 38 laboratory confirmed cases, and a 
total of 49 deaths were reported. Also EVD was 
found in United State, Spain, Mali, Senegal and 
Nigeria due to the mechanisms of travel-related 
and healthcare transmission [28]. A country can 
be considered free of Ebola virus transmission 
when the double maximum incubation period (42 
days) has elapsed since the last patient in 
isolation, became laboratory negative for EVD 
[29]. According to the World Health Organization 
update on January 28, 2015, a total of 26290 
confirmed, probable, and suspected cases of 
Ebola and 10890 deaths had been reported from 
the three West African countries (Guinea, Liberia, 
and Sierra Leone) where transmission has been 
widespread and intense. Distribution of cases is 
including Guinea, 3581 cases and 2381 deaths; 
Liberia, 10322 cases and 4608 deaths; Sierra 





Clinical finding and pathogenesis 
 
    As mentioned, EVD is a highly contagious 
anthropozoonotic disease that caused by exposure 
with infected blood or body fluids. Disease 
symptoms start 2 to 21 days after exposure with 
an average incubation period of 7-10 days [31]. 
Incubation period may vary according to the route 
of infection. It has been demonstrated that 
incubation period for cases of Zaire Ebola virus 
infection due to injection is 3-6 days; versus 5-9 
days for contact exposures however most of 
patients become symptomatic after 8 to 9 days. 
EVD is responsible for a spectrum of clinical 
manifestations that can be ranged from 
nonspecific symptoms such as flu-like symptoms, 
sudden high fever, weakness, malaise, headache, 
diarrhea, and vomiting which can be confused 
with typhoid fever, malaria, meningococcemia, 
and other bacterial infections to a multisystem 
organ failure, viral hemorrhagic fever, 
hypovolemia, and disseminated intravascular 
coagulation. In severe course, patients often die 
within 8 to 9 days. Although patient who survives 
beyond 2 weeks tends to survive, after 2 weeks 
may be complicated by arthralgias, ocular disease, 
tinnitus, pericarditis, orchitis, and suppurative 
parotitis [31, 32]. 
In patients with EVD, gastrointestinal 
abnormalities such as severe watery diarrhea, 
nausea, vomiting and abdominal pain may 
develop after about 5 days from the initial non-
specific symptoms. Also, the symptoms of 
respiratory disorders include chest pain, shortness 
of breath, cough, headache or confusion. 
Neurological manifestations include prostration, 
delirium, confusion and coma [33]. The signs of 
hemorrhagic manifestations in EVD patients can 
include petechiae, ecchymosis, mucosal 
hemorrhage (especially in the conjunctiva), 
oozing from venipuncture sites and post-mortem 
evidence of visceral hemorrhagic effusions. 
Several studies indicated that unexplained 
bleeding manifestations are not always present in 
EVD while fever (39–40°C) can be as the most 
common finding in the early phase of the disease 









Nonpruritic maculopapular rash is usually noted 
between 5–7 days on the trunk and upper arms, 
ending with desquamation in the convalescence 
period. This sign is a valuable diagnostic key and is 
usually followed by desquamation in survivors [10]. 
The most common signs and symptoms reported 
from West Africa during the current outbreak from 
symptom-onset to the time the case was detected 
include: fever (87%), fatigue (76%), vomiting 
(68%), diarrhea (66%), and loss of appetite (65%) 
[3].  The detailed pathogenesis of the disease is not 
well known and is sparse [34]. Ebola virus enters 
through inhalation, parenteral route, mucous 
membranes and abrasions and breaks in the skin. It 
seems that the route of infection can be affected the 
disease course and outcome. Studies on nonhuman 
primates have shown that Ebola virus has a broad 
cell tropism and infects many cell types; including 
monocytes, macrophages, dendritic cells, 
endothelial cells, fibroblasts, hepatocytes, adrenal 
cortical cells and epithelial cells. These cells seem to 
have pivotal roles in dissemination of the virus. 
However, in vitro studies have also demonstrated 
that virus can detect in semen, genital secretions 
fibroblasts, hepatocytes, endothelial cells and 
adrenal cells of infected patients. Infection can be 
disseminated via infected monocytes, macrophages 
and dendritic cells and their migration to the spleen 
and also, migration of lymph nodes to other tissues 
[35, 36].  
Transmission 
     Although natural reservoir host of Ebola viruses 
is unknown, recent studies exhibited that fruit bats 
may be as a reservoir for Ebola virus species. 
Animal-to-human transmission may be the result of 
contact with an infected animal. Ebola virus seems 
to spread by direct contact infectious secretions with 
abrasions of the skin or mucosal or by objects such 
as needles. Therefore, healthcare providers, family 
and friends who are in close contact with Ebola 
patients are known as the most groups at risk of 
transmission. Human-to-human transmission of the 
virus also may be occurred through direct contact 
with body fluids of symptomatic patients and/or 
infected cadavers and leads to outbreaks [32, 37]. It 
is documented that outbreak of Ebola virus in Sudan 
and Zaire, Gabon and Democratic Republic of the 
Congo (DRC) respectively were due to the  reuse of 
contaminated needles, Butchering of a chimpanzee 
and consumption of infected bats [38, 39]. In 
general, the role of droplets or airborne transmission 
in disease is not well known and it was 
demonstrated among non-human primates in an 
experimental setting. Laboratory exposure through 
needle stick and reuse of contaminated needle has 
been reported [37]. The milestone for controlling of 
EVD is to interrupt the chain of virus transmission. 
Early identification and isolation of symptomatic 
patients and contact tracing and follow-up 
surveillance of all contacts are important issues for 
restriction EVD transmission and control the further 
spread of the infection. In accordance with the 
maximum incubation period of EVD, suggested 
time for follow up of contacts is about 21 days. 
International air travelers and Healthcare workers 
(HCWs) are important high-risk groups for 
transmission. Tracking should be done for all of 
high-risk groups [40, 41]. 
According to the WHO definition for EVD a 
suspected case was  
1)  Any person with abrupt onset of high fever and 
contact with patient with EVD or contact with a 
sick/dead animal 
2) Any person with abrupt onset of high fever and at 
least of three of the following symptoms: headache, 
loss of appetite, swallowing and/or breathing 
difficulties, anorexia, hiccup, vomiting, diarrhea, 
unexplained bleeding, aching muscles or joints, 
lethargy, stomach pain, or any sudden death due to 
an unknown cause [28]. 
According to the WHO definition for EVD in 
category Person under Investigation (PUI) is a 
person who has both consistent signs or symptoms 
and risk factors as follows: 
1)  Elevated body temperature or subjective fever or 
symptoms, including severe headache, fatigue, 
muscle pain, vomiting, diarrhea, abdominal pain, or 
unexplained hemorrhage. 
2)  An epidemiologic risk factor within 21 days 
before the initiation of symptoms. 
3)  Confirm of cases as Ebola virus infection is 
based on category PUI with a laboratory 
confirmation of Ebola virus infection [3].  
Diagnosis  
    Early recognition and rapid and accurate 
diagnosis of Ebola infection is essential to 
implement appropriate control measures. The initial 
diagnosis of Ebola infection is based on clinical 
assessment. Laboratory findings of EVD are 
classified in 4 classes include:  
 




1) Hematologic findings (thrombocytopenia, 
leucopenia, granulocytosis, lymphopenia, anemia 
and coagulation abnormalities)  
2) Hepatic findings (transaminitis)  
3) Renal findings (elevated creatinine level, 
proteinuria and hematuria)  
4) Metabolic findings (low calcium level) [42, 43]. 
In general, laboratory detection of EVD is based on 
two ways measurement of host specific immune 
responses to infection and detection of viral 
particles, or particle components in infected 
individuals. Laboratory diagnosis for EVD is 
generally done in reference laboratory. Laboratory 
findings can support the diagnosis of Ebola viral 
disease but are not specific [32]. The diagnosis of 
Ebola virus infection is an actual challenge. Due to 
nonspecific symptoms, particularly early in the 
course, diagnosis of EVD can often be confused 
with other more common infectious diseases such as 
tropical diseases like malaria, typhoid fever, 
shigellosis, leptospirosis, yellow fever, and 
Chikungunya fever [44]. Well–equipped laboratory 
with biosafety level 4 are necessity for laboratory 
diagnosis of EVD [43]. There are several laboratory 
techniques developed for diagnosis of EVD 
including RT-PCR, ELISA, antigen-capture 
detection test, immunohistochemistry staining, 
electron microscopy and cell culture. Nowadays, the 
primary assays for laboratory diagnosis of EVD are 
RT-PCR and ELISA which can be positive from the 
third day in blood. RT-PCR is an important method 
for diagnosis of EVD that can detect virus 
approximately 10 days after symptoms appear [44]. 
ELISA is the most generally assay for antibody 
detection. IgM antibodies can be determined from 
day 2 after the onset of symptoms and decrease to 
undetectable levels 30–168 days after infection. 
Specific IgG antibodies appear after 6–18 days of 
the onset of the symptoms and stable for years. It is 
better that all these techniques perform after 
inactivation of virus. An efficient way to inactivate 
the virus for antigen and antibody detection is using 
of heat, gamma irradiation and denaturation of the 
proteins with guanidinium isothiocyanate [45, 46].  
Treatment 
    There is no specific treatment available for EVD 
patients despite of considerable advances in 
chemotherapeutic agents that can be used for 
increasing survival chance of them. The main 
therapeutic options are supportive and symptomatic 
treatment such as preserving fluid and electrolyte 
balance, blood pressure and maintaining a stable 
level of oxygen saturation [2, 47]. For as much as 
this disease may be mistaken with malaria and other 
tropical diseases, empiric treatment of malaria, 
broad-spectrum antibiotics, analgesics and 
antipyretics should be initiated immediately while 
obtaining the confirmed diagnosis [2]. ZMapp as an 
experimental monoclonal antibody can be effective 
in treatment of infected non-human primates. In 
addition, various chemotherapeutic agents can be 
used for treatment of EVD such as: recombinant 
human activated protein C, recombinant nematode 
anticoagulant protein c2 (rNAPc2), anti-sense 
phosphorodiamidate morpholino oligomers, broad 
spectrum nucleoside analog BCX4430, 
Favipiravir/T-705 and interferons, cyanobacterial 
lectins cytovirin (SVN), mAbs and Ad-vectored 
interferon (IFN)-α [13, 15, 48, 49]. Newly 
developed drugs are including small interfering 
ribonucleic acids and adenosine analogues that 
target viral proteins activities. The majority of these 
therapeutic options exhibited effectiveness in 
animals but so far, has not been tested in Ebola 
patients [50]. 
Prevention 
     Previously, due to low frequency of Ebola cases 
the usefulness of an Ebola virus vaccine was 
disputed but with frequent outbreaks in past decade, 
vaccine was considered by several companies. In 
general, there are 3 types of vaccine including live 
attenuated, killed or inactivated and subunit 
vaccines. Live attenuated viruses and killed or 
inactivated in compare with recombinant vaccine 
have lower immunogenicity. Human adenovirus-
type-5, vesicular stomatitis virus, human 
parainfluenza virus type 3, virus-like particles and 
recombinant Ebola virus without VP35 are potential 
vaccine candidates against Ebola virus and also have 
shown effectiveness in rodents and non-human 
primates [51, 52]. Human adenovirus-type-5 vectors 
have been greatest success rate to protect non-                                                              
human primates from lethal Ebola virus challenge 
[53, 54].  
One of the potential limitations in use of adenovirus 
based recombinant vaccines is natural host 
immunity response to adenovirus-type-5 that could 
potentially interfere in the generation of high titer 
immunity. There are attempts to utilize CMV and 
rabies virus as a platform to prepare and test an 
 




Ebola virus vaccine but needs to be further 
evaluated [55].  
 
CONCLUSION  
     In conclusion, Ebola virus infection as a zoonotic 
disease with high mortality rate should be more 
focused not only in endemic area but also in 
throughout the world.  Unfortunately there is no 
standard and specific treatment for EVD therefore 
prevention is the best strategy to control of outbreak 
and infection caused by this bacterium. Awareness 
of the disease’s symptoms and transmission routes, 
use of active surveillance systems, rapid 
identification of cases, contact tracing, isolation of 
patients, appropriate use of personal protective 
equipment (PPE) and improvement of community 
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